Italian pharma major Recordati (RECI: MI) saw its shares dip 3.75% to 50.10 euros this morning, despite posting a set of strong financial results.
Consolidated net revenue for the first nine months of 2024 was 1,743.1 million euros ($1.88 billion), up 12.0% versus the first nine months of 2023 or 9.3% on a like-for-like basis at constant exchange rates (CER). This was driven by strong business momentum across both specialty & primary care and rare diseases. T
Adjusted net income of 445.4 million euros rose9.5%. Net income of 338.4 million euros increased 11.1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze